405: An obesity drug deep-dive, and peptides move mainstream

The obesity drug market faces a high bar for innovation as recent data from the American Diabetes Association conference reveals underwhelming efficacy and tolerability for new GLP-1 candidates compared to existing treatments like Zepbound. While Eli Lilly’s retatrutide shows potential for superior weight loss, concerns persist regarding real-world safety and the necessity of placebo-controlled trials in a landscape where effective alternatives are already available. Beyond metabolic health, the biotech sector marked a record-breaking $670 million IPO for Parabolis Medicines and a $10.6 billion acquisition of New Valent by GSK. The conversation shifts to the controversial peptide BPC-157, which has gained popularity in the biohacking community despite limited human clinical data. Reporter Sara Talpos highlights the regulatory uncertainty surrounding this compound as an FDA advisory committee prepares to evaluate whether to permit its compounding and wider public access.